Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10091	Companies
206472	Keywords
136638	Articles
109434	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 08/05/2024 at 16:18, 1 year 7 months ago

Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningf
Jaguar Health, Inc. issued a letter to shareholders regarding the upcoming webcast to review second-quarter earnings and clinical data from the recent phase 3 OnTarget trial of crofelemer for breast and lung cancer patients

Crofelemer Webcast Jaguar Health Breast Cancer Lung Cancer
BRIEF

published on 08/02/2024 at 16:05, 1 year 7 months ago

Elaine Elisabetsky, PhD, to Discuss Plant-Based Schizophrenia Treatments

Jaguar Health Magdalena Biosciences Schizophrenia Plant-based Medicine Ethnopharmacology
BRIEF

published on 08/02/2024 at 16:05, 1 year 7 months ago

Elaine Elisabetsky, PhD, discutera des traitements contre la schizophrénie à base de plantes

Magdalena Biosciences Schizophrénie Santé Jaguar Médecine À Base De Plantes Ethnopharmacologie
PRESS RELEASE

published on 08/02/2024 at 16:00, 1 year 7 months ago

Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Dr. Elisabetsky conducts research on plant-based medicines for mental health conditions. Jaguar out-licenses botanical drug for schizophrenia treatment to Magdalena Biosciences

Jaguar Health Magdalena Biosciences Schizophrenia Dr. Elisabetsky Plant-based Medicines
BRIEF

published on 06/26/2024 at 14:35, 1 year 8 months ago

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement

Crofelemer Jaguar Health Nasdaq Compliance OnTarget Trial Cancer Supportive Care
BRIEF

published on 06/26/2024 at 14:35, 1 year 8 months ago

Jaguar Health retrouve sa conformité avec l'exigence de prix acheteur du Nasdaq

Crofelemer Santé Jaguar Conformité Au Nasdaq Essai OnTarget Soins De Soutien Contre Le Cancer
PRESS RELEASE

published on 06/26/2024 at 14:30, 1 year 8 months ago

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
JAGX's securities remain listed and traded on Nasdaq as Jaguar announces regaining compliance with Nasdaq's bid price requirement. Updates on cancer supportive care drug crofelemer OnTarget trial results expected by July 23, 2024

Crofelemer Nasdaq Jaguar Health OnTarget Trial JAGX
BRIEF

published on 06/21/2024 at 22:20, 1 year 9 months ago

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Crofelemer Podcast Jaguar Health OnTarget Trial World Rainforest Day
BRIEF

published on 06/21/2024 at 22:20, 1 year 9 months ago

Jaguar Health annonce l’approbation de toutes les propositions lors de l’assemblée annuelle des actionnaires de juin 2024

Crofelemer Podcast Santé Jaguar Essai OnTarget Journée Mondiale De La Forêt Tropicale
PRESS RELEASE

published on 06/21/2024 at 22:15, 1 year 9 months ago

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Jaguar Health, Inc. to report pivotal phase 3 OnTarget trial results for cancer supportive care drug crofelemer by July 23, 2024. Investor webcast and podcast interview updates included

Crofelemer Investor Webcast Jaguar Health OnTarget Trial Cancer Supportive Care

Accesswire

Published on 03/25/2026 at 13:30, 5 hours 10 minutes ago

Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/25/2026 at 13:30, 5 hours 10 minutes ago

Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification
Published on 03/25/2026 at 13:30, 5 hours 10 minutes ago

Strategic Metals Closes Project Sale
Published on 03/25/2026 at 13:25, 5 hours 15 minutes ago

Predictiv AI Expands Active Deployment of CloudRep.ai Across Healthcare, Retail, Real Estate, Travel and Global Markets
Published on 03/25/2026 at 13:20, 5 hours 20 minutes ago

Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update

View all ACCESSWIRE

EQS Group

Published on 03/25/2026 at 18:00, 39 minutes ago

LIGHTON: Information relative au nombre total de droits de vote et d'actions composant le capital social au 28 février 2026.
Published on 03/25/2026 at 18:00, 39 minutes ago

LIGHTON: Information concerning the total number of voting rights and shares in the share capital as of 28 february 2026.
Published on 03/25/2026 at 17:51, 48 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/25/2026 at 17:40, 1 hour ago

Press release Mobimo: Wangen-Brüttisellen approves Torfmatt project
Published on 03/25/2026 at 17:40, 1 hour ago

Communiqué de presse: Wangen-Brüttisellen dit oui au projet Torfmatt

Les Echos

Published on 03/25/2026 at 18:31, 8 minutes ago

Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 18:31, 8 minutes ago

Performance soutenue des Investissements et déploiement actif de la stratégie
Published on 03/25/2026 at 18:06, 33 minutes ago

LNA SANTE : Résultats Annuels 2025
Published on 03/25/2026 at 18:00, 40 minutes ago

Covivio Hotels - Modalités de mise à disposition des documents préparatoires à l’assemblée générale mixte du 14 avril 2026
Published on 03/25/2026 at 17:45, 55 minutes ago

Combined General Meeting on May 05, 2026: publication of the notice of Meeting

View all LES ECHOS COMFI WIRE